Radioactive Plaque Treatment for Eye Tumours: Risks and Planning
Radioactive plaque treatment, also called plaque brachytherapy, is a form of local radiotherapy used for selected tumours inside the eye. A small radioactive disc is temporarily secured to the outside of the eye so that radiation is directed towards the tumour. It is not appropriate for every eye tumour and it does not guarantee preservation of the eye, vision or life.
Why specialist assessment matters
An ocular oncology team should establish the diagnosis and assess the tumour’s type, position, size and relationship to structures needed for vision. The assessment can include a detailed eye examination and imaging, with other investigations when clinically indicated. Treatment decisions may involve an ophthalmic oncologist, radiation specialist, medical physicist and other cancer professionals.
The proposed isotope, dose, plaque design and time in place are individual treatment-plan decisions. A timetable or result quoted for one patient, centre or study should not be treated as a promise for another person.
What treatment can involve
The plaque is placed during an operation and positioned over the tumour. It remains in place for the period calculated by the treating team and is then removed in a further procedure. Anaesthesia, admission, medicines and radiation-safety arrangements vary. Patients must follow the treating centre’s instructions while the plaque is present; generic online instructions should not replace them.
After removal, the eye and tumour need continued review. The effect of radiation develops over time, so follow-up can include eye imaging, vision and pressure checks and monitoring for delayed radiation effects. Where the diagnosis has a risk of spreading beyond the eye, the oncology team should also explain systemic surveillance.
Benefits, limits and alternatives
Plaque brachytherapy concentrates radiation near a tumour and may allow the eye to remain in place in selected cases. Tumour control and useful vision are different outcomes: treatment can control a tumour while vision still deteriorates because of the tumour, radiation effects or other eye disease.
Depending on the diagnosis and clinical findings, alternatives may include observation, another local treatment, proton or other external-beam radiotherapy, surgical resection or removal of the eye. No option is universally superior. The team should explain why its recommendation fits the individual case, the uncertainties involved and what would happen if the first treatment did not achieve its aim.
Possible risks
Risks can include pain, inflammation, bleeding, infection, cataract, raised eye pressure or glaucoma, retinal detachment and damage to the retina, macula, optic nerve, sclera or other nearby tissue. Vision may be reduced or lost. The tumour may persist or recur, and further treatment or removal of the eye may be necessary. Some effects can appear months or years later.
The probability and importance of each risk depend on the tumour and its location, the radiation plan, the condition of the eye and the patient’s wider health. A specialist who has examined the patient should give the personalised risk discussion.
Verify any Revitalize treatment proposal
Revitalize should not be assumed to provide or arrange ocular plaque brachytherapy unless the named ocular oncology specialist, hospital and treatment pathway have been confirmed in writing for the individual case. Before paying or travelling, ask for the exact diagnosis under consideration, the clinician’s name and registration, the licensed hospital, the multidisciplinary plan and who is responsible for radiation delivery, emergency care and long-term follow-up.
The general Revitalize doctor directory and hospital information do not by themselves confirm that this specialist cancer service is available. Contracted providers and clinical capabilities can change, so the written treatment plan is decisive.
Travel and continuity of care
International travel should be planned around specialist review, not a fixed recovery schedule. Confirm how long the team requires the patient to remain nearby, what radiation-safety restrictions apply, which records will be supplied and how the treating centre will communicate with the patient’s local ophthalmology and oncology teams.
Seek urgent medical advice for sudden loss or marked change of vision, severe or worsening eye pain, increasing redness or swelling, discharge, heavy bleeding, new flashes or floaters, a curtain-like shadow, fever or any symptom identified by the treating team. Use the centre’s emergency instructions.
Questions to ask the specialist team
- What is the confirmed or suspected tumour diagnosis?
- Why is plaque brachytherapy recommended for this tumour?
- What are the realistic aims for tumour control, eye retention and vision?
- What alternatives are suitable and what are their trade-offs?
- Which short- and long-term complications are most relevant to this eye?
- Who will place and remove the plaque, and where?
- What monitoring is required for the eye and for disease elsewhere?
- Who provides urgent care after the patient returns home?
For independent patient information, see Moorfields Eye Hospital NHS Foundation Trust’s guidance on treatment with a radioactive plaque and the NHS overview of eye cancer.